Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (7) , 1122-1139
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (71704064)
- Natural Science Foundation of Guangdong Province, China (2017A030310174)
- Fundamental Research Funds for the Central Universities (21616324)
This publication has 42 references indexed in Scilit:
- Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in GreeceCancer Management and Research, 2013
- Total cost comparison in relapsed/refractory multiple myelomaJournal of Medical Economics, 2013
- Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and WalesThe European Journal of Health Economics, 2012
- Improved curve fits to summary survival data: application to economic evaluation of health technologiesBMC Medical Research Methodology, 2011
- Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomibJournal of Medical Economics, 2011
- Clinical and Economic Outcomes Attributable to Health Care–Associated Sepsis and PneumoniaArchives of internal medicine (1960), 2010
- Recombinant Erythropoietin for Chemotherapy-Related AnaemiaPharmacoEconomics, 2007
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- Racial differences in patients’ perceptions of debilitated health statesJournal of General Internal Medicine, 1999
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987